The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Currie Craig J.   Poole Chris D.   Tetlow Tony   Holmes Paul   McEwan Phil  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Poole Chris D.   Tetlow Tony   McEwan Phil   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-48

Informa Healthcare

Access to resources Recommend Favorite

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

By Peterson Gregory E.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2613-2619

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*

By Tunis Sandra L.   Minshall Michael E.   Conner Christopher   McCormick John I.   Kapor Jovana   Yale Jean-François   Groleau Danielle  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1273-1284

Informa Healthcare

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite